Ligand id: 9096

Name: domagrozumab

No information available.
Summary of Clinical Use
Domagrozumab is being evaluated in a Phase II safety, efficacy, pharmacokinetics and pharmacodynamics clinical trial in patients suffering from Duchenne muscular dystrophy (NCT02310763).
Mechanism Of Action and Pharmacodynamic Effects
In normal physiology myostatin (also known as growth differentiation factor 8, abbreviated GDF-8) is an autocrine myokine that acts on muscle cells to inhibit myogenesis i.e. muscle cell growth and differentiation. Inhibition of myostatin improves muscle histology, mass, and function. It is hypothesised that myostatin inhibitors may slow disease progression in DMD by delaying fibrotic infiltration in dystrophic muscle [1] as well as potentially increasing myocyte growth and differentiation.